【导读】酪氨酸激酶抑制剂（Tyrosine kinase inhibitors, TKIs）显著改善了表皮生长因子受体（epidermal growth factor receptor， ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Zai Lab Limited (NASDAQ:ZLAB) said on Monday that China’s National Medical Products Administration has accepted the label ...

We modelled the ability of pathways activated by tyrosine kinase receptors to induce GBM formation in mice with the RCAS/tv-a system, which allows post-natal gene transfer in a cell-type ...

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive ...

HUTCHMED (China) Limited ("HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

Zai Lab Limited (NASDAQ: ZLAB) shares barely moved Monday, on word China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib ...

At least as important will be what I anticipate is the proof of principle of this important strategy." We are pleased to present the white paper of that group, the International Receptor Tyrosine ...

China’s National Medical Products Administration (NMPA) has accepted Innocare Pharma Ltd.’s NDA for its second-generation pan-tropomyosin receptor kinase inhibitor, zurletrectinib (ICP-723), for ...